- Home
- IMPP vs KROS Comparison
IMPP vs KROS Comparison
Compare IMPP & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMPP | KROS |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.7M | 206.0M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IMPP | KROS |
|---|---|---|
| Price | $5.28 | $11.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $21.86 |
| AVG Volume (30 Days) | ★ 352.0K | 185.4K |
| Earning Date | 05-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | $51.79 | N/A |
| Revenue Next Year | $6.97 | $2,751.79 |
| P/E Ratio | $3.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.15 | $9.69 |
| 52 Week High | $6.57 | $22.55 |
Technical Indicators
Market Signals| Indicator | IMPP | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 58.00 | 51.77 |
| Support Level | $4.64 | $10.64 |
| Resistance Level | $5.30 | $11.56 |
| Average True Range (ATR) | 0.22 | 0.50 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 63.89 | 59.06 |
Price Performance
Historical ComparisonAbout IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.